Setrusumab

N/A

Report date: 2023/10/19 17:36:25

Base Information

Drug NameSetrusumab
Drug Alias NameAnti-sclerostin-monoclonal-antibodyNOV-3MOR-05813BPS-804UX143
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionSclerostin inhibitors
TargetsSclerostin
Therapy Area/IndicationsHypophosphatasiaRenal Insufficiency, ChronicOsteoporosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMorphosys AgNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesMereo Biopharma Group PlcUltragenyx Pharmaceutical Inc
Inactive CompaniesNovartis Pharma Ag
Active IndicationsOsteogenesis Imperfecta
Inactive IndicationsHypophosphatasiaRenal Insufficiency, ChronicOsteoporosis +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank